Manufacturing concerns spike Nabriva’s plans to launch its first antibiotic — for now
In another setback for the beleaguered antibiotics field, Nabriva Therapeutics says the FDA rejected its fosfomycin for complicated urinary tract infections.
Importantly, the biotech says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
